This study will validate in-vivo retinal hyperspectral imaging (HSI) as biomarker in preclinical human AD and elucidate the neuropathologic sequence of Aβ evolutional changes in preclinical to late stage AD in post-mortem tissue.
|Effective start/end date||11/16/20 → 11/16/23|
- Retispec, Inc. (Agmt 11/16/20)
- Alzheimer's Drug Discovery Foundation (Agmt 11/16/20)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.